Revolutionizing Antiviral Treatment

Empowering billions with groundbreaking science to combat viral diseases at scale.

Revolutionizing Antiviral Treatment

Empowering billions with groundbreaking science to combat viral diseases at scale.

We are at the forefront of a new era in antiviral therapy. Our mission is to bring hope to billions by delivering accessible, life-changing medicines that address critical unmet needs across global health.

explore our impact

+

B

Lives impacted by infectious diseases

by targeting these pervasive global health challenges, we aim to transform treatment and improve outcomes for a significant portion of the world’s population.

With our pioneering discovery of the allosteric Thumb-1 cryptic site of the RdRp, and the development of orally administered broad-spectrum therapeutics, we are transforming the fight against the world’s most pervasive viral threats.

Explore our pipeline

lead asset

MDL-001

lead asset

MDL-001

lead asset

MDL-001

Early Clinical

Our lead drug candidate MDL-001 is a first-in-class and best-in-class orally administered broad-spectrum antiviral therapy targeting the allosteric Thumb-1 cryptic site of the RdRp, a novel and highly conserved target critical for viral replication. MDL-001 has demonstrated exceptional potential to combat a wide range of infectious diseases, offering a transformative solution for patients.

targetING viral diseases

SARS-CoV-2

hCoV-α

hCoV-β

Norovirus

Influenza A

Influenza B

HCV

infectious Disease Pipeline

With groundbreaking advancements in antiviral science, we are transforming the fight against infectious diseases.

Indication

SARS-CoV-2 (and VOCs)

VIRAL FAMILY

Coronaviridae

Therapeutic Class

Best-in-class

PATIENT POPULATION

760M

IND Enabling

INDICATION

SARS-CoV-2 (and VOCs)

VIRAL FAMILY

Coronaviridae

Therapeutic Class

Best-in-class

PATIENT POPULATION

760M

IND Enabling

Indication

SARS-CoV-2 (and VOCs)

VIRAL FAMILY

Coronaviridae

Therapeutic Class

Best-in-class

PATIENT POPULATION

760M

IND Enabling

Explore Our Pipeline →

We’re building alliances to out-license our innovative programs and advance custom antiviral drug discovery mandates. Together, we can catalyze global solutions for infectious diseases.

partner with us

We’re building alliances to out-license our innovative programs and advance custom antiviral drug discovery mandates. Together, we can catalyze global solutions for infectious diseases.

partner with us

Experienced Leadership

Our team of experts have devoted their careers to combating infectious diseases. Their unparalleled expertise and passion drive our mission to revolutionize antiviral treatment.

Dr. David (Davey) Smith

Lead Clinical Advisor

An infectious disease expert who led one of the largest clinical trials under Operation Warp Speed and served as protocol chair for the ACTIV-2 study, which tested antibodies and experimental therapeutics for mild and moderate COVID-19.

Dr. David (Davey) Smith

Lead Clinical Advisor

Dr. David (Davey) Smith

Lead Clinical Advisor

Sumit Chanda, Ph.D

Preclinical Development Partner & Advisor

A leading researcher focused on RNA viruses posing pandemic threats, leveraging cutting-edge technologies to study virus-host interactions and innate immunity.

Sumit Chanda, Ph.D

Preclinical Development Partner & Advisor

A leading researcher focused on RNA viruses posing pandemic threats, leveraging cutting-edge technologies to study virus-host interactions and innate immunity.

Sumit Chanda, Ph.D

Preclinical Development Partner & Advisor

A leading researcher focused on RNA viruses posing pandemic threats, leveraging cutting-edge technologies to study virus-host interactions and innate immunity.

Arnab Chatterjee, Ph.D

Preclinical Development Partner & Advisor

A medicinal chemist with expertise in respiratory and infectious diseases, driving the development of multiple clinical candidates for global health challenges.

Arnab Chatterjee, Ph.D

Preclinical Development Partner & Advisor

A medicinal chemist with expertise in respiratory and infectious diseases, driving the development of multiple clinical candidates for global health challenges.

Arnab Chatterjee, Ph.D

Preclinical Development Partner & Advisor

A medicinal chemist with expertise in respiratory and infectious diseases, driving the development of multiple clinical candidates for global health challenges.

Dr. Launa Aspeslet

Senior Scientific & Clinical Advisor

A pharmaceutical industry leader with extensive C-suite experience overseeing clinical trials and scaling organizations in public biotech companies.

Dr. Launa Aspeslet

Senior Scientific & Clinical Advisor

A pharmaceutical industry leader with extensive C-suite experience overseeing clinical trials and scaling organizations in public biotech companies.

Dr. Launa Aspeslet

Senior Scientific & Clinical Advisor

A pharmaceutical industry leader with extensive C-suite experience overseeing clinical trials and scaling organizations in public biotech companies.

Adolfo Garcia-Sastre, Ph.D

Preclinical Development Partner & Advisor

A pioneer in influenza research, serving as Director of the Global Health and Emerging Pathogens Institute, with over 480 publications advancing the understanding of viral replication.

Adolfo Garcia-Sastre, Ph.D

Preclinical Development Partner & Advisor

A pioneer in influenza research, serving as Director of the Global Health and Emerging Pathogens Institute, with over 480 publications advancing the understanding of viral replication.

Adolfo Garcia-Sastre, Ph.D

Preclinical Development Partner & Advisor

A pioneer in influenza research, serving as Director of the Global Health and Emerging Pathogens Institute, with over 480 publications advancing the understanding of viral replication.

Kris White, PhD

Preclinical Development Partner & Advisor

Leads a laboratory established to counteract and prepare for pandemic-level viral threats, focusing on resistance-refractory antivirals and synergistic drug combinations.

Kris White, PhD

Preclinical Development Partner & Advisor

Leads a laboratory established to counteract and prepare for pandemic-level viral threats, focusing on resistance-refractory antivirals and synergistic drug combinations.

Kris White, PhD

Preclinical Development Partner & Advisor

Leads a laboratory established to counteract and prepare for pandemic-level viral threats, focusing on resistance-refractory antivirals and synergistic drug combinations.

Our Impact

A world where pandemics are a thing of the past, where the most vulnerable are shielded from viral threats, and where innovation continuously redefines the boundaries of possibility.

Our Impact

A world where pandemics are a thing of the past, where the most vulnerable are shielded from viral threats, and where innovation continuously redefines the boundaries of possibility.

Our Impact

A world where pandemics are a thing of the past, where the most vulnerable are shielded from viral threats, and where innovation continuously redefines the boundaries of possibility.